https://www.fiercebiotech.com/biotech/merck-stops-phase-3-tigit-trial-lung-cancer-futility-and-sees-immune-side-effects-again
efti looking more like a target for Merck. I believe IMMP also holds a patent for use with ANY PD-1 blocker, which would include generic keytruda when its patent runs out soon for Merck. OS data from HNSC out later this year will back up the possibility of PH3 success in lung.
Efti looking good after second TGIT fail
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |